Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook
1. MRK reported Q3 EPS of $2.58, beating estimates of $2.35. 2. Total sales reached $17.28 billion, exceeding expectations of $16.96 billion. 3. Keytruda sales increased 10% to $8.14 billion, showing strong demand. 4. 2025 earnings guidance raised to $8.93-$8.98 per share, above Wall Street's estimate. 5. Merck is exploring M&A opportunities, targeting deals up to $15 billion.